Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 7/20 | 0.50 |
| ▸ | CDK8 | P49336 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549163 | 1.00 | CCNC (0.50) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL3539831 | 0.86 | CCNC (0.47) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL3539836 | 0.86 | CCNC (0.47) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL4071696 | 0.80 | CCNC (0.54) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL23580797 | 0.79 | CCNC (0.73) | CCNCCDK8KDM4EALDH1A1CA1 | |
| SCHEMBL23580798 | 0.79 | CCNC (0.73) | CCNCCDK8KDM4EALDH1A1CA1 | |
| SCHEMBL9756928 | 0.79 | CCNC (0.50) | CCNCCDK8KDM4EALDH1A1TDP1 | |
| SCHEMBL23579958 | 0.79 | MIF (0.53) | CCNCCDK8KDM4EALDH1A1CA1 | |
| SCHEMBL9756966 | 0.79 | CCNC (0.50) | CCNCCDK8KDM4EALDH1A1MEN1 | |
| SCHEMBL23579960 | 0.79 | MIF (0.53) | CCNCCDK8KDM4EALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114401969-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2022-04-26 | — | — | CN | disclosed |
| WO-2018140876-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2820014-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Amgen Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130890-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8198282-B2 | Substituted azaquinazolines having an antiviral action | AICURIS GMBH & CO. KG (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | US | disclosed |
| US-7662822-B2 | Substituted azaquinazolines having an antiviral action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | BAYER HEALTHCARE AG (DE) | 2008-06-05 | — | — | US | disclosed |
| CN-1980925-A | Substituted azaquinazolines with antiviral activity | AICURIS GMBH & CO KG (DE) | 2007-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | PDE10A, PDE1B, PDE9A | CCNC 3507/4885CDK8 1891/4885KDM4E 3889/4885 |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | ZC3HAV1, EIF2AK2, IRF3 | CCNC 190/4885CDK8 155/4885KDM4E 1009/4885 |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | EIF2AK2, TPMT, IRF3 | CCNC 348/4885CDK8 32/4885KDM4E 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.